All In Biotech

NDA 022433 · Astrazeneca

Brilinta

Ticagrelor · Oral · P2Y12 Platelet Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: May 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Jul 20, 2011

Approved uses

7

Original approval plus efficacy supplements

Registered trials

486

104 Phase 3, 49 recruiting

FAERS reports

32,137

24,607 serious, 3,464 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: BLEEDING RISK • BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). • Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage • ( 4.1 , 4.2 ). • Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG) ( 5.1 , • 6.1 ). • If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of • subsequent cardiovascular events ( 5.2 ). WARNING: BLEEDING RISK See full prescribing information for complete boxed warning. • BRILINTA, like other antiplatelet agents, can cause significant, • sometimes fatal bleeding. ( 5.1 , 6.1 ) • Do not use BRILINTA in patients with active pathological • bleeding or a history of intracranial hemorrhage. ( 4.1 , 4.2 ) • Do not start BRILINTA in patients undergoing urgent coronary •...

What it is approved for

From the label in effect May 7, 2026.

BRILINTA is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction BRILINTA is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ] . While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) BRILINTA is indicated to reduce the risk of stroke in patients with acute...

Mechanism: Ticagrelor and its major metabolite reversibly interact with the platelet P2Y 12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • BRILINTA · TICAGRELOR 60MG · TABLET, ORAL · Prescription · TE AB
  • BRILINTA · TICAGRELOR 90MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ticagrelor" as an intervention, any sponsor and status, largest first.

All 486 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea4,051
  • myocardial infarction2,804
  • death1,733
  • fatigue1,558
  • off label use1,534
  • chest pain1,485
  • dizziness1,272
  • contusion1,090
  • drug interaction997
  • asthenia937
  • malaise899
  • haemorrhage888

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20083
20098
20105
201152
20121,008
20131,229
20141,596
20152,107
20164,309
20173,151
20182,956
20192,251
20202,191
20212,195
20221,881
20232,106
20242,176
20251,702
20261,211

Recalls

2 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • May 25, 2017 · Class I · Terminated

    Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Brilinta (Ticagrelor)

2024 spending

$685M

Beneficiaries

242,931

1,029,007 claims

Per beneficiary

$2,822

$7.26 per unit

View as table
YearSpending
2020$588,513,924
2021$602,371,203
2022$638,382,092
2023$691,725,954
2024$685,497,437

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,048 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.